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Abstract The adenovirus E1B-55K protein is a multifunctional
phosphoprotein that regulates nuclear to cytoplasmic export of
host cell and viral mRNAs during lytic viral growth. E1B-55K
also blocks apoptosis by binding and functionally inactivating the
human tumor suppressor protein p53. Here, we show that E1B-
55K interacts with histone deacetylase 1 (HDAC1) and the
transcriptional corepressor protein mSin3A, both in the adeno-
virus-transformed 293 cell line and during a lytic adenovirus
infection. Furthermore, we show that the central amino acids
156^261 in E1B-55K are necessary for efficient HDAC1
interaction. Importantly, the E1B-55K/mSin3A/HDAC1 com-
plex is also enzymatically active, catalyzing deacetylation of a
histone substrate peptide. Collectively, our results suggest that
E1B-55K interaction with mSin3A/HDAC1 containing com-
plexes may be significant for one or several of the multiple
activities ascribed to this protein. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
The adenovirus (Ad) E1B-55K protein is a multifunctional
phosphoprotein that serves several functions during virus
growth. For example, the E1B-55K protein interacts and
functionally inactivates the cellular tumor suppressor protein
p53 (reviewed in [1]). This interaction is speci¢c since Ad5
E1B-55K does not interact with the structural and functional
p53 homologous proteins, p51 and p73 [2]. E1B-55K interacts
with the amino-terminal transactivation domain of p53 [3].
This interaction blocks p53 as a transcriptional activator of
several promoters, such as mdm2, cyclin G, bax and
p21WAF1 [4]. Furthermore, tethering E1B-55K to a promoter
represses basal and activated transcription from that pro-
moter [5,6]. Available data suggest that the silencer activity
of E1B-55K requires an unknown cellular corepressor protein
that copuri¢es with RNA polymerase II [5].
Additionally, a protein complex consisting of the adenoviral
E1B-55K and the E4-ORF6 proteins mediates the selective
transport of viral mRNAs late during lytic virus growth (re-
viewed in [7]). The observation that the Ad5 E1B-55K protein
interferes with mRNA export in Saccharomyces cerevisiae in-
dicates that this protein is the primary adenovirus protein
blocking host cell mRNA export [8]. Interestingly, E1B-55K
interaction with the host cell protein, E1B-AP5 (E1B-55K-
associated protein 5) appears to be critical for the E1B-55K-
dependent inhibition of host cell mRNA export [9]. Recent
data indicate that the E1B-55K protein shuttles between the
cytoplasm and the nucleus, also in the absence of E4-ORF6
[10].
Reversible acetylation of core histones is an important reg-
ulatory mechanism controlling gene expression. In general,
histone acetylation is associated with activated transcription,
and deacetylation with transcriptional repression. The acety-
lation and deacetylation reactions are catalyzed by a number
of evolutionary conserved histone acetyltransferases (HATs)
and histone deacetyltransferases (HDACs), respectively (re-
viewed in [11]). In mammalian cells, HDAC1 and HDAC2
are found in a multiprotein complex with mSin3A, the mouse
homologue of the yeast global transcription repressor protein
SIN3 [12]. The mSin3A/HDAC complex has been implicated
as a corepressor complex utilized by a diverse collection of
transcriptional repressor proteins, including SMRT, N-CoR,
Mad, MeCP2, Ski (reviewed in [13]).
Here we report that the adenovirus-2 E1B-55K protein
makes a speci¢c complex with HDAC1 in vitro and in tran-
siently transfected cells. In vivo, E1B-55K appears to exist in
a complex with mSin3A and HDAC1. Importantly, the E1B-
55K/mSin3A/HDAC1 complex is enzymatically active, cata-
lyzing deacetylation of a histone substrate peptide. Collec-
tively, our results suggest that E1B-55K binding to mSin3A/
HDAC1 complexes may be signi¢cant for one or several of
the multiple functions associated with this protein.
2. Materials and methods
2.1. Plasmids
Plasmid maps, sequences are available on request, or at http://
www.bmc.uu.se/IMIM/res/GA.html. Cloning and ampli¢cation of
E1B-55K expressing plasmids were done in Escherichia coli SURE
cells (Stratagene). Plasmid pBSE1B-55K (kindly provided by E.
Bridge) encodes the adenovirus type 2 E1B-55K protein, and was
the starting material for reconstruction of all E1B-55K expressing
plasmids. Plasmid pHis-E1B-55K was generated by recloning E1B-
55K into the pQE30 expression vector (Qiagen). For eukaryotic ex-
pression, E1B-55K was recloned into pcDNA3.1 (Invitrogen).
pGSTHDAC1 was generated by recloning the HDAC1 cDNA from
pING14AHDAC1 [14] into pGEX2T (Pharmacia). Plasmids pIN-
G14AHDAC1, pCMV5P3THDAC1(FL) and pGEXp53 were gener-
ously provided by Tony Kouzarides and Klas Wiman, respectively.
2.2. Puri¢cation of proteins expressed in bacteria
His-E1B-55K expression was induced in 1 l cultures at 37‡C to an
optical density of 0.4. IPTG was added to a ¢nal concentration of 0.4
mM and the incubation continued, at room temperature, for an addi-
tional 16 h. Cells were collected and His-E1B-55K puri¢ed on Ni-
NTA as described by the manufacturer (Qiagen). Expression and
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puri¢cation of GST-HDAC1, GST-p53 and GST were done as pre-
viously described [15].
2.3. In vitro transcription/translation
35S-Labeled wild-type E1B-55K and deletion mutant proteins were
synthesized by coupled in vitro transcription/translation using the
reticulocyte TnT system (Promega). The template DNA was generated
by polymerase chain reaction (PCR) ampli¢cation using a forward
primer containing a T7 RNA polymerase promoter and a Kozak se-
quence positioned upstream of the translation initiation codon, and a
reverse primer complementary to the 3P end of the gene. Carboxy-
terminal E1B-55K deletion mutants were generated by restriction en-
donuclease cleavage of the PCR template DNA; PvuII (mutant 1^
155), HindIII (mutant 1^261), BglII (mutant 1^435). E1B-55K mutant
261^421 was generated by PCR and recloned into pcDNA3.1(+).
HDAC1 was transcribed from plasmid pING14AHDAC1.
2.4. In vitro binding assays
Approximately 400 ng of His-E1B-55K or His-p32 [16] was incu-
bated in 400 Wl of NET(0.2) bu¡er (50 mM Tris^HCl pH 7.5, 150 mM
NaCl, 5 mM EDTA, plus 0.2% NP40) with 35S-labeled HDAC1 for
30 min at 4‡C. Anti-His (Clontech) or anti-FLAG (Kodak) antibodies
were added to the reaction mixture and incubation continued for 1 h.
Precipitates were collected on protein A Sepharose (Amersham Phar-
macia Biotech) and washed four times with NET(0.2) bu¡er. GST
pull-down experiments were performed with 1 Wg of GST, GST-
HDAC1 or GST-p53 proteins incubated with in vitro translated
E1B-55K proteins in NET (0.5% of NP40) bu¡er. Proteins were sep-
arated on sodium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE) and visualized by autoradiography.
2.5. In vivo co-immunoprecipitation
Subcon£uent monolayers of COS-7 cells were transfected with 2 Wg
of HA-HDAC1 plus or minus 2 Wg of pcDNAE1B-55K plasmids.
Transient transfections were done by using FuGene6 (Roche) accord-
ing to the manufacturer’s protocol. Cells were lysed with NET(0.2)
containing COMPLETE Protease Inhibitor Mix (Roche), and the cell
suspension passed ¢ve times through a 21 G needle. The soluble ex-
tract was precleared with 20 Wl of 50% protein A Sepharose slurry.
The precleared extracts were immunoprecipitated with 1 Wg of anti-
HA (clone 12CA5), anti-His antibodies or with 20 Wl of anti-E1B-55K
antibody (clone 2A6 [17]) for 1 h. 20 Wl of a 50% protein A Sepharose
slurry was added and incubation continued for another 2 h. The
precipitates were washed four times in NET(0.2) bu¡er, separated
on SDS^PAGE, transferred to a nitrocellulose membrane, and probed
with the appropriate antibodies. Co-immunoprecipitations from 293
cells and late adenovirus-infected HeLa cells were done in a similar
way. For 293 cells, a total of 3 mg of protein was incubated with 1 Wg
of anti-mSin3A, anti-HDAC1 or anti-Gal4 antibodies (all antibodies
from Santa Cruz). Protein A Sepharose bound immunocomplexes
were recovered after overnight incubation and washed in NET(0.2)
bu¡er. For HeLa cells, nuclear extracts were prepared from unin-
fected and late adenovirus-infected cells as previously described [18].
Approximately 200 Wg of precleared nuclear extracts was used in the
assay and immunoprecipitated with the same antibodies as described
for 293 cells. Proteins were visualized on nitrocellulose ¢lter by West-
ern blot analysis using the enhanced chemiluminescence system
(Amersham Pharmacia Biotech).
2.6. Histone deacetylation activity assay
As substrate, a peptide corresponding to the ¢rst 24 amino acids of
bovine H4 was synthesized and chemically acetylated with 0.1 mCi of
[3H]sodium acetate (DuPont) in the presence of BOP and triethyl-
amine [19]. Immunoprecipitations were done using anti-mSin3A,
E1B-55K or three di¡erent p53 antibodies (Ab-3, Calbiochem; DO-
1, Santa Cruz; and 421, generously provided by Toivo Maimets) per
1 mg of total 293 cell extract in NET(0.2) bu¡er. Protein A Sepharose
beads were washed four times with NET(0.2) bu¡er and once with
HDAC(10) bu¡er (10 mM Tris pH 7.5, 10 mM NaCl, 10% glycerol).
Beads were ¢nally resuspended in 100 Wl of HDAC(10) bu¡er, mixed
with 0.5 Wg of acetylated peptide (50 000 cpm) and incubated at 37‡C
for 20 min. Reactions were terminated by addition of 1 M HCl/0.16
M acetic acid and extracted with ethyl acetate. The ethyl acetate
fraction was counted in a liquid scintillation counter. Deacetylation
was blocked by incubating the immunoprecipitates with 300 nM of
trichostatin A (TSA) for 15 min on ice before addition of the peptide
substrate. Samples were assayed in duplicate in three di¡erent experi-
ments.
3. Results
3.1. E1B-55K interacts with HDAC1 in vitro
To investigate whether the Ad2 E1B-55K protein can inter-
act with HDAC1, we performed in vitro co-immunoprecipita-
tion experiments. In these experiments, bacterially expressed
His-E1B-55K was incubated with 35S-labeled HDAC1. Reac-
tion mixtures were immunoprecipitated with an anti-His anti-
body. As shown in Fig. 1, mixing HDAC1 and His-E1B-55K
results in a co-precipitation of HDAC1 (lane 3), in a reaction
that requires His-E1B-55K (lane 5). Importantly, under the
same experimental conditions, HDAC1 did not bind to an
unrelated His-tagged protein, His-p32 (lane 2). Furthermore,
HDAC1 was not precipitated by a control, anti-FLAG anti-
body (lane 4). Also, E1B-55K did not show a signi¢cant bind-
ing to in vitro translated luciferase protein (lane 7), further
emphasizing that the E1B-55K/HDAC1 interaction was spe-
ci¢c. Collectively, our results show that E1B-55K interacts
speci¢cally with HDAC1 under in vitro co-immunoprecipita-
tion assay conditions.
To delineate the amino acid sequences in E1B-55K required
for HDAC1 interaction, we performed the reverse assay using
bacterially produced GST-HDAC1 in a pull-down assay with
in vitro translated 35S-labeled E1B-55K deletion mutant pro-
teins (Fig. 2). GST-p53 was used as a positive control in this
assay. As shown in Fig. 2, GST-HDAC1 and GST-p53 inter-
act with the full-length E1B-55K protein (1^495), mutants
E1B-55K (1^435) and E1B-55K (1^261), but not with E1B-
55K (1^155). Using the amino-terminal deletion mutant E1B-
55K (261^421) shows that GST-p53, and particularly GST-
HDAC1, interacted weakly with a carboxy-terminal fragment
of E1B-55K.
Based on these results, we conclude that HDAC1 interacts
primarily with the central part of E1B-55K (amino acids 156
and 261) and weakly with amino acids 261^421. We further
Fig. 1. The adenovirus-2 E1B-55K protein interacts with HDAC1.
In vitro translated 35S-labeled HDAC1 and 35S-labeled luciferase
were incubated together with His-p32 or His-E1B-55K and immuno-
precipitated with an anti-His antibody (lanes 2, 3, 5 and 7) or a
control anti-FLAG antibody (lane 4). Lanes 1 and 6 contain 1/5
and 1/10 of the input protein used in binding reactions. The posi-
tions of protein size markers (in kDa) are indicated on the left.
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conclude that the binding speci¢city of GST-HDAC1 and
GST-p53 to E1B-55K was identical, whereas the binding af-
¢nity varied slightly (Fig. 2).
3.2. E1B-55K interacts with HDAC1 in vivo
To analyze whether E1B-55K and HDAC1 also interact in
vivo, we performed co-immunoprecipitation experiments in
COS-7 cells, transiently transfected with plasmids encoding
E1B-55K and HA-HDAC1. As shown in Fig. 3, immunopre-
cipitation with anti-E1B-55K antibody brought down HA-
HDAC1 (lane 6). This e¡ect was E1B-55K speci¢c since the
same antibody did not immunoprecipitate HA-HDAC1 in the
absence of E1B-55K (lane 5). Furthermore, immunoprecipita-
tion with an irrelevant anti-His antibody did not precipitate
either E1B-55K (data not shown) or HA-HDAC1 (lanes 8 and
9). Importantly, HA-HDAC1 was expressed at the same level
irrespective of E1B-55K cotransfection (lanes 2 and 3).
Based on these results, we conclude that E1B-55K binds
speci¢cally to HA-HDAC1 in vivo, in transiently transfected
COS-7 cells.
3.3. E1B-55K interacts with HDAC1 and the mSin3A
corepressor protein in vivo
To further demonstrate the relevance of the E1B-55K/
HDAC1 interaction, we determined whether an interaction
could be detected in 293 cells, an adenovirus-transformed
cell line expressing E1B-55K [20]. Since previous studies
have shown that HDAC1 exists in a multiprotein complex,
which includes mSin3A [12], we also assayed for a possible
interaction between E1B-55K and mSin3A. As shown in Fig.
4A, immunoprecipitation with anti-mSin3A brought down
high levels of E1B-55K and HDAC1 (lane 2). This interaction
was speci¢c since we could not detect E1B-55K, mSin3A or
HDAC1 in immunoprecipitates using an unrelated anti-Gal4
antibody (lane 4). We also detected a weak precipitation of
E1B-55K with the anti-HDAC1 antibody (lane 3). Despite the
fact that anti-mSin3A and anti-HDAC1 antibodies precipi-
tated similar amounts of HDAC1, the anti-mSin3A antibody
precipitated signi¢cantly more E1B-55K (lanes 2 and 3). This
result indicates that E1B-55K interaction with mSin3A does
not require HDAC1. Potentially, E1B-55K may interact di-
rectly with mSin3A, or alternatively with other members of
mSin3A complex. A strong interaction between E1B-55K and
mSin3A was also detected in nuclear extracts prepared from
late adenovirus-infected HeLa cells (Fig. 4B), suggesting a
Fig. 2. Mapping of the primary amino acid sequences in E1B-55K
required for HDAC1 and p53 interaction. GST, GST-HDAC1 and
GST-p53 were incubated with equal amounts of 35S-labeled wild-
type and mutant E1B-55K proteins. Proteins were separated on 12%
SDS^PAGE. The position of protein size markers (in kDa) is indi-
cated on the left.
Fig. 3. E1B-55K interacts with HDAC1 in vivo. COS-7 cells were
transfected with pCMV5P3THDAC1(FL) plus or minus
pcDNAE1B-55K. Cell extracts were split into equal fractions and
immunoprecipitated with an anti-E1B-55K antibody (lanes 4^6) or a
non-speci¢c control anti-His antibody (lanes 7^9). Lanes 1^3 show
the input, corresponding to 1/10 of the cell extract used for immu-
noprecipitation with the anti-E1B-55K or the anti-His antibodies
(lanes 4^9). Proteins were transferred onto a nitrocellulose mem-
brane and HDAC1 visualized by probing with an anti-HA anti-
body.
Fig. 4. E1B-55K interacts with HDAC1 and mSin3A expressed in vivo. A: Cell extracts prepared from 293 cells were immunoprecipitated with
anti-mSin3A (lane 2), anti-HDAC1 (lane 3) or with anti-Gal4 antibodies (lane 4). B: Nuclear extracts prepared from uninfected or adenovirus-
infected HeLa cells were immunoprecipitated with anti-mSin3A (lanes 3 and 4) or with anti-Gal4 antibodies (lane 5). In both panels, precipi-
tated proteins were sequentially detected on the same Western blot ¢lter by probing with anti-E1B-55K, anti-mSin3A or anti-HDAC1 antibod-
ies. Input (lane 1) represents 1/30 of the extracts used for immunoprecipitations.
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potential signi¢cance of these interactions for lytic virus
growth.
Collectively, our results show that E1B-55K interacts with
mSin3A and HDAC1 in vivo. The data are compatible with,
but do not prove, the hypothesis that E1B-55K forms a multi-
meric complex with mSin3A and HDAC1. Potentially, E1B-
55K interacts independently with HDAC1 and mSin3A.
3.4. The E1B-55K and mSin3A/HDAC complex is
enzymatically active
The establishment of an interaction between E1B-55K and
mSin3A/HDAC1 is interesting, and potentially very impor-
tant. However, a key question is whether this interaction gen-
erates a complex that is enzymatically active. To test this, we
immunoprecipitated the endogenously expressed mSin3A and
E1B-55K proteins in 293 cell extracts and incubated the pre-
cipitate with a 3H-acetylated peptide corresponding to the 24
N-terminal amino acids of histone H4. Deacetylation was
measured as a release of [3H]acetate, which was quanti¢ed
by scintillation counting. As shown in Fig. 5, anti-mSin3A
immunoprecipitation recruited a high deacetylation activity
(lane 1), an activity that was reduced to background levels
by treatment with TSA (lane 2), a potent HDAC inhibitor
[21]. Interestingly, immunoprecipitation of E1B-55K also pre-
cipitated a substantial amount of deacetylase activity, only 5-
fold less compared to mSin3A (compare lanes 1 and 3). This
result is important, because it demonstrates that E1B-55K
interaction with mSin3A/HDAC (Fig. 4) generates an enzy-
matically active complex. Treatment of E1B-55K immunopre-
cipitates with TSA reduced deacetylation back to the back-
ground levels (compare lanes 3 and 4). Similarly,
immunoprecipitation of E1B-55K from adenovirus-infected
nuclear extracts resulted in a recruitment of deacetylase activ-
ity (data not shown).
We also tested whether the enzymatic activity recruited by
E1B-55K was indirect, mediated by p53. Recent studies have
suggested that p53 binds to the mSin3A/HDAC1 complex in
murine and human cells [22]. Therefore, it became important
to determine whether the E1B-55K recruitment of HDAC
activity was indirect, mediated through an interaction between
p53 and HDAC1. However, as shown in Fig. 5 (lanes 5^7), we
could not detect a recruitment of a deacetylation activity in
293 cells by immunoprecipitation of p53 with three di¡erent
p53 antibodies. Thus, we conclude that p53 immunoprecipi-
tated from 293 cells does not bring down a HDAC activity.
Collectively, these results demonstrate that the E1B-55K
and mSin3A/HDAC1 complex is enzymatically functional,
and furthermore suggest that recruitment of this enzymatic
activity is not mediated by p53.
4. Discussion
Here we demonstrate that the Ad2 E1B-55K protein inter-
acts with HDAC1, and mSin3A containing complexes in a
way that generates an enzymatically active complex.
Two distinct classes of HDACs have been identi¢ed in high-
er eukaryotes, based on their homology with yeast HDACs.
Class I HDACs (HDAC1^3) show a homology to the yeast
Rpd3 protein, and class II HDACs (HDAC4^6) are homolo-
gous with the yeast Hda1 protein [23]. Since yeast Rpd3 and
Hda1 interact speci¢cally with di¡erent accessory proteins, it
appears likely that the class I and II HDACs expressed in
higher eukaryotes will also make functionally distinct com-
plexes [13]. Interestingly, Ad5 E1B-55K does not interact
with HDAC4, a member of class II HDACs [24]. Thus,
E1B-55K may show speci¢city towards the class I HDACs
in vivo. Importantly, the interaction between E1B-55K and
mSin3A/HDAC1 generates a complex that has a deacetylation
activity (Fig. 5).
What is the biological signi¢cance of the E1B-55K interac-
tion with mSin3A/HDAC1? The most obvious hypothesis is
that E1B-55K repression of p53 as a transcriptional activator
protein requires recruitment of this complex. Recruitment of
HDAC containing complexes has been coupled to transcrip-
tional repression by several repressor proteins [13]. Although
an attractive model, we have not been able to demonstrate
that cotransfection of a plasmid expressing HDAC1 signi¢-
cantly a¡ects the repressive e¡ect of E1B-55K on p53-induced
transcription (data not shown). Similarly, Gal4-E1B-55K re-
pression of basal transcription from a herpes simplex thymi-
dine kinase promoter, containing Gal4 DNA binding sites,
was not sensitive to TSA treatment (data not shown). Collec-
tively, these experiments argue against a function of the E1B-
55K/mSin3A/HDAC1 complex in transcriptional regulation.
Similar results have previously been reported by others
[24,25]. However, the function of the E1B-55K/mSin3A/
HDAC complex may be promoter speci¢c. Precedence for
such a promoter-dependent mechanism comes from studies
of pRB repression of transcription. Here it has been shown
that pRB inhibits the adenovirus major late promoter by
HDAC recruitment, but not the SV40 enhancer or the herpes
simplex thymidine kinase promoters [26]. It should be noted
that in all our experiments, we have used arti¢cial promoter
constructs. Thus, analyzing the e¡ect of E1B-55K/mSin3A/
HDAC1 on native p53 regulated promoters may give a di¡er-
ent result.
Alternatively, it is possible that transcriptional repression
by E1B55K is not mediated by the deacetylation activity of
Fig. 5. E1B-55K interaction with mSin3A/HDAC generates an enzy-
matically active complex. Extracts from 293 cells were immunopreci-
pitated with anti-mSin3A, anti-E1B-55K, anti-p53 or anti-HA anti-
bodies. Deacetylase activity was detected as radioactivity released
from a 3H-labeled acetylated histone H4 peptide [19]. Pretreatment
with 300 nM TSA was done for 15 min before addition of the sub-
strate peptide. The results represent the average of three di¡erent
experiments, assayed in duplicate.
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HDAC1, but by the activity of other subunits in the mSin3A
complex. For example, mSin3A itself can mediate transcrip-
tion repression in the absence of deacetylation. In fact, mSi-
n3A binds the general transcription factor TFIIB, suggesting
that mSin3A may interfere with formation of a functional
preinitiation complex [27].
Although much of the current work has focused on tran-
scriptional regulation through acetylation/deacetylation of
core histones, it is important to note that recent studies
have shown that a number non-histone proteins are substrates
for acetylation. For example, p53, GATA1, E2F1, Importin-K
all have been shown to be acetylated by the same HATs
acetylating core histones [28]. Acetylation of these proteins
regulates many functions in the cell, including DNA binding,
protein^protein interactions and protein stability. Very little is
known about the deacetylation of non-histone proteins. How-
ever, the E2F1 transcription factor has been shown to be
deacetylated by HDAC1 [29]. It appears likely that future
studies will further increase the number of HDAC targets,
and furthermore show that reversible acetylation is an impor-
tant mechanism regulating a diverse set of cellular functions.
Of particular interest is the recent ¢nding that Importin-K is
acetylated by p300 [30]. Importin-K is a nuclear import factor,
initiating the nuclear entry of target proteins [31]. This ¢nding
may provide a link between the E1B-55K nucleo-cytoplasmic
shuttling activity [10] and E1B-55K interaction with HDAC1
(Fig. 1). Although attractive, this hypothesis remains to be
experimentally tested.
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